Brigatinib is specifically designed for patients with ALK-positive NSCLC. This means that their cancer cells have a genetic mutation in the ALK gene. It is typically prescribed when the disease has spread to other parts of the body and has not responded to other ALK inhibitors, such as crizotinib.
